174 related articles for article (PubMed ID: 37437865)
1. Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics.
Nayak V; Patra S; Singh KR; Ganguly B; Kumar DN; Panda D; Maurya GK; Singh J; Majhi S; Sharma R; Pandey SS; Singh RP; Kerry RG
Environ Res; 2023 Oct; 235():116573. PubMed ID: 37437865
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions.
Fu L; Li Z; Ren Y; Yu H; Liu B; Qiu Y
Biochem Pharmacol; 2023 Mar; 209():115449. PubMed ID: 36754153
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
Guo P; Yang J; Huang J; Auguste DT; Moses MA
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
6. Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.
Farheen J; Hosmane NS; Zhao R; Zhao Q; Iqbal MZ; Kong X
Mater Today Bio; 2022 Dec; 16():100450. PubMed ID: 36267139
[TBL] [Abstract][Full Text] [Related]
7. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
Li C; Brant E; Budak H; Zhang B
J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
[TBL] [Abstract][Full Text] [Related]
9. CRISPR: A Promising Tool for Cancer Therapy.
Mohammad-Rafiei F; Safdarian E; Adel B; Vandchali NR; Navashenaq JG; Gheibihayat SM
Curr Mol Med; 2023; 23(8):748-761. PubMed ID: 35748558
[TBL] [Abstract][Full Text] [Related]
10. CRISPER/Cas in Plant Natural Product Research: Therapeutics as Anticancer and other Drug Candidates and Recent Patents.
Dey A; Nandy S
Recent Pat Anticancer Drug Discov; 2021; 16(4):460-468. PubMed ID: 34911411
[TBL] [Abstract][Full Text] [Related]
11. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
12. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches.
Ahmed MZ; Badani P; Reddy R; Mishra G
J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111
[TBL] [Abstract][Full Text] [Related]
13. Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective.
Ilahibaks NF; Hulsbos MJ; Lei Z; Vader P; Sluijter JPG
Adv Exp Med Biol; 2023; 1396():315-339. PubMed ID: 36454475
[TBL] [Abstract][Full Text] [Related]
14. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Strategies of Clustered Regularly Interspaced Palindromic Repeats-Cas Systems for Different Viral Infections.
Wahid B; Usman S; Ali A; Saleem K; Rafique S; Naz Z; Ahsan Ashfaq H; Idrees M
Viral Immunol; 2017 Oct; 30(8):552-559. PubMed ID: 28825529
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.
Boucher P; Cui X; Curiel DT
J Control Release; 2020 Nov; 327():788-800. PubMed ID: 32891680
[TBL] [Abstract][Full Text] [Related]
18. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
Front Immunol; 2022; 13():865424. PubMed ID: 35784280
[TBL] [Abstract][Full Text] [Related]
19. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
Shalaby K; Aouida M; El-Agnaf O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
